The active ingredient semaglutide is now available in tablet form as an alternative to weekly injections for weight management, according to the European Medicines Agency (EMA). Marketed under the brand name Wegovy, the oral treatment launches amid high anticipated demand from patients and pharmacies, following regulatory approval for adults with obesity or overweight alongside at least one weight-related comorbidity.
How Oral Semaglutide Works and Differs from Injections
Semaglutide mimics the natural hormone GLP-1 to regulate hunger, satiety, and food intake, according to the EMA. Dr. Ulrike Thieme, medical director at the telemedical provider ZAVA, explains that the medication does more than simply suppress appetite. It slows gastric emptying, particularly at the start of treatment, and supports blood sugar regulation by increasing insulin secretion and lowering glucagon when blood glucose is elevated, as noted by ZAVA.
The transition from a weekly injection to a daily pill involves a significant change in dosage figures. According to the EMA, the oral medication is available in strengths of 1.5, 4, 9, and 25 milligrams.
Clinical Efficacy and Strict Dosing Rules
In the OASIS 4 trial cited by Martin Schulze, pharmacist and head of pharmaceutical customer support at mycare.de, participants taking oral semaglutide achieved an average weight loss of around 14 percent after 64 weeks, compared to two to three percent in the placebo group, according to reporting by Frankfurter Rundschau. The EMA notes that the exact mechanism of weight loss remains not fully clarified.
Administration rules for the tablet differ strictly from the injection schedule. The EMA specifies that patients must take the tablet once daily in the morning on an empty stomach after at least eight hours of fasting. Patients must then wait at least 30 minutes before eating, drinking, or taking other oral medications, whereas the injection is administered once a week.
Side Effects and Health Risks
Because both formulations contain the same active ingredient, the fundamental side effect profile remains comparable, according to Dr. Thieme. Gastrointestinal issues represent the most frequent adverse events, including nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, and reflux. Data from the OASIS-4 trial showed that 74 percent of patients on oral semaglutide experienced gastrointestinal side effects, compared to 42.2 percent in the placebo group. Dr. Thieme clarifies that most of these reactions were mild to moderate rather than severe.
Less common but medically significant risks include pancreatitis, gallstones, gallbladder inflammation, severe gastrointestinal complications, allergic reactions, and acute kidney injury resulting from severe dehydration caused by vomiting or diarrhea. For patients with type 2 diabetes, hypoglycemia is a risk when the drug is combined with insulin or specific blood-sugar-lowering medications, and diabetic retinopathy can worsen in susceptible individuals, according to ZAVA.
Insurance Coverage and Long-Term Management
Statutory health insurance in Germany classifies semaglutide used strictly for weight loss as a lifestyle medication under Section 34 of the Social Code Book V (SGB V), meaning insurance generally does not cover the cost, according to Martin Schulze. Patients must pay for the prescription treatment out of pocket, which Schulze notes places added pressure on lawmakers to reevaluate policies surrounding chronic obesity treatment.
Experts emphasize that medication alone is insufficient to maintain weight loss long-term. Nina Meyer and clinical guidance indicate that successful weight management requires medical supervision alongside structured behavioral, nutritional, and physical activity programs. Follow-up data from studies like STEP-1 demonstrate that patients typically regain a substantial portion of lost weight after discontinuing semaglutide injections, highlighting that the oral tablet lowers psychological barriers to treatment but retains the clinical requirements for long-term care.
Worth a look